Shark Alert Company: Puma biotechnology Inc Quote: $PBYI BT:$22.85 / @ market ST: $28 (at the moment pending to change) SL: - (very volatile name would trigger a SL quickly) Short Interest: 15.50% Next earnings:- Reason for trade: Most recent earnings the stock took a very big hit on low sales and low guidance going forward, however this a is a very solid company with a solid drug pipeline and the moment this is a quick swing trade we can be out of the trade by the end of the day/week. Stock has been extremely oversold has a good chance to rebound strong. Description: Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California. Analyst ratings: Stock Price Target PBYIHigh | $68.00 | Median | $36.00 | Low | $23.00 | Average | $42.78 | Current Price | $22.76 | Nov-02-18 | Downgrade | JP Morgan | Neutral → Underweight | |
| Nov-02-18 | Downgrade | BofA/Merrill | Buy → Underperform | |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight | $75 |
| Sep-17-18 | Initiated | Goldman | Sell | $42 |
| May-11-18 | Reiterated | Stifel | Buy | $95 → $87 |
|
Strategy: Timing the approval of the HER2- Mutant Breast cancer phase III and market approval is very tough however once we see the buying increase again similar to last approval we will re enter the name.(for long term holders) Catalyst to go higher: Phase III trails and market approvals. Insider buying and selling (13fs/tape readings: Very strong this week News: https://www.zacks.com/stock/news/335116/puma-biotech-pbyi-q3-loss-narrows-nerlynx-pulls-stock-down https://www.fool.com/investing/2018/11/01/why-puma-biotechnology-inc-stock-is-getting-crushe.aspx https://www.businesswire.com/news/home/20181101006024/en/ https://www.businesswire.com/news/home/20181016006087/en/ | 
